Immunic is moving forward with Nurr1 program testing aimed at pushing beyond what the company describes as the inflammation ceiling in multiple sclerosis (MS). The Phase III candidate vidofludimus calcium will evaluate whether combining DHODH inhibition with direct neuroprotective effects can slow MS progression. The approach targets both inflammatory and neurodegenerative components—an area of sustained interest for MS drug developers seeking activity beyond standard immunomodulation. If successful, the results could reshape the therapeutic positioning for MS candidates that aim to broaden benefit profiles; if not, it will further clarify the clinical limits of this pathway combination.